Legend Biotech (LEGN) Stock Forecast & Price Target

Legend Biotech Corp is experiencing significant advancements with its CAR T cell therapy, CARVYKTI, which has treated over 8,500 patients globally and is projected to have a peak potential of approximately $5 billion, demonstrating robust year-over-year growth of 80% and sequential growth of 19%. The recent expansion in global capacity at Raritan is expected to strengthen CARVYKTI's ability to meet increasing demand, particularly in earlier treatment lines, while the addition of the OS label enhances its market viability and appeal among physicians. Management's positive outlook is supported by improved treatment strategies that mitigate adverse effects, which could bolster the therapy's adoption and ultimately accelerate the overall expansion of BCMA treatments.

Legend Biotech Corp faces significant challenges that contribute to a negative outlook on its stock, primarily due to reimbursement pressures surrounding its CAR-T therapy, Carvykti, which may limit its market potential. The company has encountered heightened competition from other clinical-stage CAR-T therapies, potentially undermining its long-term revenue growth prospects despite projected sales nearing $2 billion by 2025. Furthermore, several operational risks, including supply constraints, delays in pipeline advancements, and partnership uncertainties, create additional headwinds that could hinder the company's financial performance.